Protara Therapeutics, Inc. — Director's Dealing 2022

Jan 31, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2022-01-28

Reporting Person: Opaleye Management Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-28	Common Stock, par value $0.001 per share	P	20000	$4.9632	Acquired	2550000	Indirect
2022-01-28	Common Stock, par value $0.001 per share	P	4031	$4.9632	Acquired	124031	Indirect

Footnotes

F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.

F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.

F3: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.9632. The range of purchase prices on the transaction date was $4.90 to $4.99 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.